Joseph Stringer
Stock Analyst at Needham
(4.86)
# 373
Out of 4,600 analysts
620
Total ratings
46.7%
Success rate
23.9%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Reiterated: Buy | $170 | $135.25 | +25.69% | 31 | Aug 5, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Hold | n/a | $478.71 | - | 33 | Aug 4, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $130 | $105.78 | +22.90% | 48 | Aug 4, 2026 | |
| STOK Stoke Therapeutics | Maintained: Buy | $40 | $31.67 | +26.30% | 46 | Aug 4, 2026 | |
| MRNA Moderna | Maintained: Hold | n/a | $56.99 | - | 43 | Jul 31, 2026 | |
| BIOA BioAge Labs | Maintained: Buy | $50 → $35 | $11.20 | +212.50% | 6 | Jul 31, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | $510 → $357 | $219.00 | +63.01% | 48 | Jul 30, 2026 | |
| PHAT Phathom Pharmaceuticals | Maintained: Buy | $28 → $22 | $8.45 | +160.36% | 75 | Jul 30, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | $86 | $55.07 | +56.16% | 44 | Jul 29, 2026 | |
| ANNX Annexon | Rated: Buy | $11 → $25 | $5.33 | +369.04% | 37 | Jul 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $110 | $54.69 | +101.13% | 41 | Jun 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 → $17 | $7.92 | +114.65% | 5 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.05 | - | 33 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $9.17 | +96.29% | 46 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.49 | n/a | 28 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.03 | n/a | 33 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.88 | n/a | 13 | Dec 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $26 | $27.15 | n/a | 5 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $166.06 | n/a | 3 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $170 | $53.07 | n/a | 2 | Apr 28, 2021 |
Gilead Sciences
Aug 5, 2026
Reiterated: Buy
Price Target: $170
Current: $135.25
Upside: +25.69%
Vertex Pharmaceuticals
Aug 4, 2026
Maintained: Hold
Price Target: n/a
Current: $478.71
Upside: -
Rhythm Pharmaceuticals
Aug 4, 2026
Maintained: Buy
Price Target: $130
Current: $105.78
Upside: +22.90%
Stoke Therapeutics
Aug 4, 2026
Maintained: Buy
Price Target: $40
Current: $31.67
Upside: +26.30%
Moderna
Jul 31, 2026
Maintained: Hold
Price Target: n/a
Current: $56.99
Upside: -
BioAge Labs
Jul 31, 2026
Maintained: Buy
Price Target: $50 → $35
Current: $11.20
Upside: +212.50%
Alnylam Pharmaceuticals
Jul 30, 2026
Maintained: Buy
Price Target: $510 → $357
Current: $219.00
Upside: +63.01%
Phathom Pharmaceuticals
Jul 30, 2026
Maintained: Buy
Price Target: $28 → $22
Current: $8.45
Upside: +160.36%
Ionis Pharmaceuticals
Jul 29, 2026
Maintained: Buy
Price Target: $86
Current: $55.07
Upside: +56.16%
Annexon
Jul 15, 2026
Rated: Buy
Price Target: $11 → $25
Current: $5.33
Upside: +369.04%
Jun 26, 2026
Maintained: Buy
Price Target: $110
Current: $54.69
Upside: +101.13%
Jun 8, 2026
Rated: Buy
Price Target: $14 → $17
Current: $7.92
Upside: +114.65%
May 12, 2026
Maintained: Hold
Price Target: n/a
Current: $1.05
Upside: -
May 7, 2026
Maintained: Buy
Price Target: $18
Current: $9.17
Upside: +96.29%
Apr 21, 2025
Rated: Hold
Price Target: n/a
Current: $2.49
Upside: n/a
Aug 16, 2024
Rated: Hold
Price Target: n/a
Current: $2.03
Upside: n/a
Dec 23, 2022
Rated: Hold
Price Target: n/a
Current: $16.88
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $30 → $26
Current: $27.15
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $166.06
Upside: n/a
Apr 28, 2021
Rated: Buy
Price Target: $170
Current: $53.07
Upside: n/a